Senju Pharmaceutical Co., Ltd.

Takeda Chemical Industries, Inc.

Yoshitomi Pharmaceutical Industries, Ltd.

Yujiro Yamamoto

Yutaka Kawamatsu

Hitoshi Ikeda

Kazumi Ogata

Kanji Meguro

Takeshi Fujita

Takahiro Ogawa

Mitsuyoshi Azuma

Hideo Terayama

Yasushi Morita

Hiroshi Kuriyama

Yoshie Ozaki

Yoshikazu Kuribayashi

An ocular antihypertensive composition for topical use which contains an effective amount of a compound represented by the formula ##STR1## or a salt thereof having, in low concentrations, intraocular pressure lowering activity in mammals, low toxicity and no influence on the pupil size and, therefore, is useful as a therapeutic agent for glaucoma, for instance. Furthermore, since the compound is effective in low concentrations, the possibility of tolerance development is considered to be scarce.

Intraocular pressure lowering composition for topical use

This invention relates to an aqueous preparation comprising a compound (A) represented by the formula: ##STR1## and at least one of cyclodextrins selected from .alpha.-cyclodextrin and dimethyl-.beta.-cyclodextrin; and a method of preparation thereof. According to the aqueous preparation of this invention, coexistence with at least one medicament selected from .alpha.-cyclodextrin and dimethyl-.beta.-cyclodextrin allows to enhance the solubility to water of compound (A) essential in this invention to such a concentration that makes an expected curative effect available and to inpart a desired stability to it. As a consequence, the aforesaid compound (A) can be utilized as a medicament for an aqueous preparation having anti-allergy action.

Aqueous preparation and method of preparation thereof

A pharmaceutical composition containing cysteine or a pharmacologically acceptable salt thereof is an effective therapeutic agent for diabetic complications, typically diabetic cataract.

Therapeutic composition for diabetic complications

Compounds of the general formula: ##STR1## wherein, R.sup.1 and R.sup.2 are, the same or different, hydrogen, a halogen, a lower alkyl, a cycloalkyl, a lower alkoxy, trifluoromethyl or a phenylalkyloxy whose phenyl ring may be substituted by one to three substituents selected from the group consisting of a halogen, a lower alkyl, a lower alkoxy, methylenedioxy and trifluoromethyl; R.sup.3 is hydrogen or methyl; R.sup.4 is carboxyl or an esterified carboxyl; and X is oxygen or sulfur, or a salt thereof. These compounds possess aldose reductase inhibitory and platelet aggregation inhibitory activities, and are of use as drugs for prevention and treatment of diabetic complications such as diabetic cataract, retinophathy, nephropathy, and neuropathy.

Thiolactam-n-acetic acid derivatives

An ophthalmic solution having anti-inflammatory action without side effects and irritativeness which comprises pranoprofen and boric acid.

Ophthalmic pranoprofen compositions

A new thiazolidine derivative of the formula: ##STR1## wherein n stands for an integer of 3 to 6 and salts thereof show strong aldose reductase inhibition and are useful for prophylaxis or therapy of diabetic cataracts and diabetic neuropathy in mammals.

Thiazolidine derivatives and production thereof

A thiazolidine derivatives of the formula: ##STR1## wherein R is a phenyl group having 2 nuclear substituent groups selected from the group consisting of a lower alkyl having 1 to 6 carbon atoms, a lower alkoxy having 1 to 7 carbon atoms, hydroxyl and a carboxylic acyloxy having 1 to 4 carbon atoms, or a phenyl group having a methylenedioxy group in adjacent positions on its ring; R.sup.1 is H or an alkyl having 1 to 6 carbon atoms, or a physiologically acceptable salt thereof is a novel compound having the activity to control certain chronic symptoms due to diabetes, such as diabetic cataract, diabetic neuropathy and diabetic retinosis.

Growing community of inventors

Suita, Japan

Yujiro Yamamoto